GSK Lapatinib Breast Cancer Development Shifts To Front-Line Setting

GlaxoSmithKline will shift its plans for the breast cancer agent lapatinib to focus on front-line use rather than refractory patients, the company said May 15

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet